Thursday, October 19, 2017 6:48:47 PM
CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl. While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance. POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.
"We are very surprised and disappointed by these results, which we will be trying to understand more fully over the coming weeks," said James E. Brown, President and CEO of DURECT Corporation. "We appreciate the efforts of the investigators and patients who participated in PERSIST, and we thank Sandoz for their support."
Recent DRRX News
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/27/2024 08:01:00 PM
- DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 03/20/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 04:37:57 PM
- DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada • PR Newswire (US) • 03/04/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:16:39 PM
- DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 11:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:15:11 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 12/01/2023 09:28:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:18 PM
- DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update • PR Newswire (US) • 11/13/2023 09:05:00 PM
- DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 11/09/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:10:15 PM
- DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality • PR Newswire (US) • 11/07/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 01:02:52 PM
- DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis • PR Newswire (US) • 09/07/2023 11:00:00 AM
- DURECT Corporation Announces Presentations in Upcoming Investor Conferences • PR Newswire (US) • 08/31/2023 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/10/2023 08:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:18:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:23:04 PM
- DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update • PR Newswire (US) • 08/09/2023 08:05:00 PM
- DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 08/03/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 09:13:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 02:38:08 PM
- DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 07/20/2023 12:00:00 PM
- DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis • PR Newswire (US) • 06/07/2023 10:00:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM